doctor head
 
  pharmacy and drugs  
search Search
 
       About us       News      A-Z Drugs      Stores      Top Drugs      Contact  
  doctor doctor hand
 
  doctor legs  
 
 
 
 

  Diseases

  Newsletter
Subscribe to our newsletter:
Name:
E-mail:
    Search results
Search results for: indications

1 - 5 of 22 <<previous | next>>

Drugs results:

Atorvastatin

Atorvastatin

Atorvastatin belong to a class of drug known as HMG CoA reductase inhibitor. This drug works by blocking the production of cholesterol (a type of fat) in the body. Indications: to reduce the amounts of low density lipoprotein or LDL (bad) cholesterol, more...

Esomeprazole pill

Esomeprazole

Esomeprazole belong to a class of drug known as proton pump inhibitor that works by decreasing the amount of hydrochloric acid produced by the parietal cells in the stomach. Indications: treatment of gastroesophageal reflux disease (GERD) and erosive more...

Fexofenadine tablets

Fexofenadine

Fexofenadine is an antihistamine that works against the naturally occurring chemical histamine in your body. Histamine is the chemical mediator for an allergic response. Antihistamine is also termed as antipruritic, “pruritus” means itchiness. It is a lon more...

Rosuvastatin pills

Rosuvastatin

Rosuvastatin is an HMG CoA reductase inhibitor which is also known as “statins” group. A class of drug that works by blocking the production of cholesterol (a type of fat) in the body. Indications: for primary hypercholesterolemia (excessive choleteste more...

Synthroid tablets

Synthroid

Also known as Synthroid, Levothyroxine is a thryroid hormone that is used when the thyroid gland does not produce enough hormone. They are also used to help decrease the size of enlarged thyroid glands (known as goiter) and to treat thyroid cancer more...

Diseases results:

Reduce cholesterol
Flatulence
Rhinitis
Cancer
High blood pressure
Abortion
Peritonitis
Acromegaly
Mycosis Fungoides

Articles results:

New Transparency Measures, European Medicines Agency
Using new powers under the revised EU pharmaceutical legislation, the Management Board agreed to publish information concerning the withdrawal by a company of its marketing authorisation application after the Agency's opinion but before the Commission's decision on marketing authorisation.The Agency will also publish information on withdrawals by applicants, and on refusals by the Agency, of applications concerning new indications for approved medicines.


European Cardiovascular Drugs Market - New Drug Areas, Classes And Combination Products To Drive Future Growth
Cardiovascular drug companies are experiencing numerous challenges in a market characterised by patent expiries and increased generic competition. To maintain growth, new drug areas and classes will require exploration. While key unmet needs offer growth opportunities, strategies centred on combination therapies, adding value through drug delivery technologies and clinical differentiation will help overcome competition from generic drug manufacturers.


Adenosine Therapeutics, LLC Initiates Phase Ib Clinical Study With ATL146e
Adenosine Therapeutics, LLC, a leading adenosine drug discovery and development company, announced today it has initiated a two-part Phase Ib study in humans to evaluate apadenoson (ATL146e), a potent selective adenosine A2A agonist, as an anti-inflammatory agent.


Takeda Announces Termination Of License Agreement For Tavocept(TM) In Japan
ASKA Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited announced the termination of the License Agreement of March 15, 2006 that had previously been entered into by Takeda, ASKA, KI Pharmaceuticals, Inc.(*) and BioNumerik Pharmaceuticals, Inc. with respect to the investigational new drug known as Tavocept(TM) for the territory of Japan.


Novartis Highlights Strong R&D Pipeline, Plans For Multiple New Product Launches And Novel Projects Moving Into Late-stage Trials
Novartis unveiled today new data on its promising pipeline amid plans for multiple new product approvals and launches over the next two years. Many of these anticipated approvals are for potentially best-in-class medicines that would advance treatment standards for patients with hypertension, diabetes, cancer and other diseases.




1 - 5 of 22 <<previous | next>>

© 2006-2010 pharmacy-and-drugs.com. All rights reserved.